Latest Licensing News

First Graphene has signed an MOU with Sixth Element to distribute its PureGRAPH® CEM additive across China, with potential for local manufacturing via a joint venture once sales milestones are met.

Starpharma has reached a key milestone in its collaboration with Radiopharm Theranostics, unlocking a $0.5 million option fee and advancing the partnership toward a potential $91 million licensing deal.

Neurotech International has received Notices of Allowance from the USPTO for two patents covering its lead drug NTI164, reinforcing its intellectual property position as it advances Phase 3 trials for autism spectrum disorder.

Echo IQ has locked in a pivotal exclusive data licensing deal with Advara HeartCare, gaining access to as many as one million de-identified echocardiography studies, a move set to turbocharge its cardiovascular AI development.

Critical Resources Limited has secured independent peer-reviewed validation of its dry supersonic deposition (DSD) cathode technology, confirming a solvent- and binder-free process with promising durability and capacity metrics. This milestone strengthens its licensing prospects as the company advances toward full solid-state battery integration.

Krakatoa Resources has launched its second underground drilling season at the Zopkhito Antimony-Gold Project, aiming to convert a foreign resource estimate into a JORC-compliant Mineral Resource Estimate while pushing early mine development.

Lode Resources has confirmed extensive near-surface gold mineralisation across multiple prospects at its Uralla Gold Project, NSW, reinforcing the potential for a large Intrusive Related Gold System.

Mesoblast has received a Biologics License Application filing number from the FDA for rexlemestrocel-L, targeting life-threatening bleeding in end-stage heart failure patients with LVADs, advancing its regulatory journey with orphan drug and RMAT designations.

Black Rock Mining has secured an extension of its US$204 million debt facility to November 2026, providing more time to finalise equity funding for the Mahenge Graphite Project in Tanzania.

archTIS has locked in a $3.2 million contract with the Australian Department of Defence, renewing Kojensi Enterprise licensing and boosting application development and maintenance services. This deal underpins a key source of recurring revenue and strengthens archTIS’s foothold in Defence’s classified ICT environment.

Chimeric Therapeutics has appointed Hawkesbury Partners to lead a strategic review aimed at exploring options to enhance shareholder value, reflecting concerns that its market cap undervalues its clinical assets and infrastructure.

Ampol has finalized its $1.165 billion acquisition of EG Australia, adding around 480 sites and 4,200 employees to its retail footprint. The deal is expected to deliver $65-80 million in synergies and boost earnings per share.